产品
编 号：F744949
分子式：C29H36N4O7
分子量：552.62
分子式：C29H36N4O7
分子量：552.62
产品类型
规格
价格
是否有货
结构图
CAS No: 1420294-56-9
产品详情
生物活性：
Zifanocycline (KBP-7072) is a semisynthetic third-generation aminomethylcycline antibiotic that inhibits the normal function of the bacterial ribosome. Zifanocycline exhibits a broad spectrum of in vitro antibacterial activity against Gram-positive and Gram-negative bacteria, including many multidrug-resistant pathogens. Zifanocycline is available in both oral and injectable formulations. Zifanocycline can be used for the research of acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections.
体内研究：
In Sprague-Dawley (SD) rats, beagle dogs, and CD-1 mice, KBP-7072 demonstrated a linear PK profile after the administration of single oral and i.v. and multiple oral doses. The oral bioavailability ranged from 12% to 32%. The mean time to maximum concentration (T max) ranged from 0.5 to 4 h, and the mean half-life ranged from approximately 6 to 11 h. The administration of oral doses in the fed state resulted in marked reductions in the maximum plasma concentration (C max) and the area under the concentration-time curve (AUC) compared with dosing in fasted animals. The mean bound fractions of KBP-7072 were 77.5%, 69.8%, 64.5%, 69.3%, and 69.2% in mouse, rat, dog, monkey, and human plasma, respectively. KBP-7072 exhibits dose-dependent potent activity against selected methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) S. aureus strains over the dose range studied (0.25 to 64?mg/kg/6 h) in neutropenic murine pneumonia infection model.
体外研究：
Zifanocycline (KBP-7072) demonstrates MIC90 values of Zifanocycline 相关抗体:
Zifanocycline (KBP-7072) is a semisynthetic third-generation aminomethylcycline antibiotic that inhibits the normal function of the bacterial ribosome. Zifanocycline exhibits a broad spectrum of in vitro antibacterial activity against Gram-positive and Gram-negative bacteria, including many multidrug-resistant pathogens. Zifanocycline is available in both oral and injectable formulations. Zifanocycline can be used for the research of acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections.
体内研究：
In Sprague-Dawley (SD) rats, beagle dogs, and CD-1 mice, KBP-7072 demonstrated a linear PK profile after the administration of single oral and i.v. and multiple oral doses. The oral bioavailability ranged from 12% to 32%. The mean time to maximum concentration (T max) ranged from 0.5 to 4 h, and the mean half-life ranged from approximately 6 to 11 h. The administration of oral doses in the fed state resulted in marked reductions in the maximum plasma concentration (C max) and the area under the concentration-time curve (AUC) compared with dosing in fasted animals. The mean bound fractions of KBP-7072 were 77.5%, 69.8%, 64.5%, 69.3%, and 69.2% in mouse, rat, dog, monkey, and human plasma, respectively. KBP-7072 exhibits dose-dependent potent activity against selected methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) S. aureus strains over the dose range studied (0.25 to 64?mg/kg/6 h) in neutropenic murine pneumonia infection model.
体外研究：
Zifanocycline (KBP-7072) demonstrates MIC90 values of Zifanocycline 相关抗体:
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备